Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02018302
NCT02018302No Longer AvailableNot Applicable

Post Study Continuation of C7 for G1D

Juan Pascual1 site in 1 countryStarted: December 23, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Sponsor
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This protocol provides ongoing access to triheptanoin for patients who did complete an initial pilot protocol, and provides the opportunity to collect long-term safety data from patients treated with triheptanoin.

Detailed Description

Only patients who completed the initial pilot study were eligible. The study is ongoing with these patients only.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
1 Month to 28 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients enrolled in the pilot trial (UTSW 122010-186)

Exclusion Criteria

  • •Subjects who did not complete the pilot trial (UTSW 122010-186)

Investigators

Sponsor
Juan Pascual
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Juan Pascual

Associate Professor, Director of the Rare Brain Disorders Program

University of Texas Southwestern Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 4
Extension to Study HMR1964A/3011 in BelgiumDiabetes Mellitus
NCT00576862Sanofi32
Completed
Not Applicable
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.Neoplasms
NCT00443534Pfizer123
Terminated
Phase 1
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Gliomas, MalignantGlioblastoma MultiformeAstrocytoma
NCT04327011Tocagen Inc.65
Completed
Phase 2
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Post-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPrimary Myelofibrosis
NCT01236638Sierra Oncology LLC - a GSK company120
Terminated
Phase 2
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.Sanfilippo SyndromeMucopolysaccharidosis (MPS)
NCT02350816Shire17